Wells Fargo’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Wells Fargo’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-250	Closed	-$2.36K	–	7170
2025 Q1	$2.36K	Hold	250	–	–	﹤0.01%	6136
2024 Q4	$3.08K	Buy	+250	New	+$3.53K	﹤0.01%	6135
2024 Q3	–	Hold	0	–	–	–	6714
2024 Q2	–	Hold	0	–	–	–	6695
2024 Q1	–	Hold	0	–	–	–	7320
2023 Q4	–	Hold	0	–	–	–	7467
2023 Q3	–	Hold	0	–	–	–	7476
2023 Q2	–	Hold	0	–	–	–	7559
2023 Q1	–	Hold	0	–	–	–	7642
2022 Q3	–	Sell	-1	Closed	–	–	6730
2022 Q2	$0	Hold	1	–	–	﹤0.01%	6871
2022 Q1	$0	Sell	1 -1	-50%	-$19	﹤0.01%	7135
2021 Q4	$0	Buy	2 +1	+100%	+$28	﹤0.01%	7272
2021 Q3	$0	Hold	1	–	–	﹤0.01%	7002
2021 Q2	$0	Buy	+1	New	+$30	﹤0.01%	6943

Other funds holding CNCR

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo's CNCR Position: Q2 2025 in Review

Wells Fargo sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2025, closing a stake of 250 shares — an estimated $2.36K sold.

Wells Fargo first reported a position in CNCR in Q2 2021 and held it in 7 quarters. The position peaked at $3.08K in Q4 2024. 1 fund tracked by Wall St. Rank holds CNCR as of Q2 2025.

Wells Fargo reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2025 after selling out during the quarter.
Wells Fargo sold 250 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2025, an estimated $2.36K.
Wells Fargo first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2021 and held it in 7 quarters.
Wells Fargo's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $3.08K in Q4 2024.
1 fund tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2025.

Based on Wells Fargo's 13F filing for Q2 2025, filed 14 Aug 2025.